Targets of Fibroblast Growth Factor 1 (FGF-1) and FGF-2 Signaling Involved in the Invasive and Tumorigenic Behavior of Carcinoma Cells
Overview
Molecular Biology
Affiliations
Fibroblast growth factor (FGF)-1 and -2 have potent biological activities implicated in malignant tumor development. Their autocrine and nonautocrine activity in tumor progression of carcinoma was investigated in the NBT-II cell system. Cells were manipulated to either produce and be autocrine for FGF-1 or -2 or to only produce but not respond to these factors. The autocrine cells are highly invasive and tumorigenic and the determination of specific targets of FGF/fibroblast growth factor receptor (FGFR) signaling was assessed. In vitro studies showed that nonautocrine cells behave like epithelial parental cells, whereas autocrine cells have a mesenchymal phenotype correlated with the overexpression of urokinase plasminogen activator receptor (uPAR), the internalization of E-cadherin, and the redistribution of beta-catenin from the cell surface to the cytoplasm and nucleus. uPAR was defined as an early target, whereas E-cadherin and the leukocyte common antigen-related protein-tyrosine phosphatase (LAR-PTP) were later targets of FGF signaling, with FGFR1 activation more efficient than FGFR2 at modulating these targets. Behavior of autocrine cells was consistent with a decrease of tumor-suppressive activities of both E-cadherin and LAR-PTP. These molecular analyses show that the potential of these two growth factors in tumor progression is highly dependent on specific FGFR signaling and highlights its importance as a target for antitumor therapy.
Haruehanroengra P, Zheng Y, Zhou Y, Huang Y, Sheng J RNA Biol. 2020; 17(11):1560-1575.
PMID: 31994439 PMC: 7567502. DOI: 10.1080/15476286.2020.1722449.
Tusup M, Kundig T, Pascolo S World J Clin Oncol. 2018; 9(3):42-55.
PMID: 29900123 PMC: 5997933. DOI: 10.5306/wjco.v9.i3.42.
Production of bFGF monoclonal antibody and its inhibition of metastasis in Lewis lung carcinoma.
Yang Y, Luo Z, Qin Y, Zhou Y, Gong L, Huang J Mol Med Rep. 2017; 16(4):4015-4021.
PMID: 28765892 PMC: 5646982. DOI: 10.3892/mmr.2017.7099.
Aberrant expression of hSef and Sprouty4 in endometrial adenocarcinoma.
Zhang H, Guo Q, Wang X, Wang C, Zhao X, Li M Oncol Lett. 2016; 11(1):45-50.
PMID: 26870165 PMC: 4727078. DOI: 10.3892/ol.2015.3835.
Masoumi-Moghaddam S, Amini A, Wei A, Robertson G, Morris D Am J Cancer Res. 2015; 5(8):2498-507.
PMID: 26396926 PMC: 4568786.